8-K: Guardant Health Reports Strong Q4, Full Year 2025 Results

Guardant Health announced robust fourth quarter and full year 2025 financial results, driven by significant growth in oncology and screening revenue, alongside a positive 2026 outlook.

Summary

• Total revenue for the fourth quarter of 2025 was $281.3 million, marking a 39% increase compared to the same period in 2024.
• Full year 2025 total revenue reached $982.0 million, a 33% increase from 2024.
• Oncology revenue grew 30% in Q4 2025 to $189.9 million, with oncology test volume increasing by 38% to approximately 79,000 tests.
• Screening revenue for Q4 2025 was $35.1 million, generated from approximately 38,000 Shield screening tests, a substantial increase from 6,400 tests in Q4 2024.
• Non-GAAP gross margin improved to 66% for both Q4 and full year 2025, up from 63% and 62% respectively in 2024.
• Net loss for Q4 2025 was $(128.5) million, and for the full year 2025 was $(416.3) million.
• Non-GAAP net loss for Q4 2025 was $(63.8) million, an improvement from $(77.3) million in Q4 2024.
• Adjusted EBITDA loss for Q4 2025 was $(64.9) million, an improvement from $(78.4) million in Q4 2024.
• Free cash flow burn improved to $(233) million for the full year 2025, compared to $(275) million in 2024.
• The company provided 2026 revenue guidance in the range of $1.25 billion to $1.28 billion, representing 27% to 30% year-over-year growth.
• Expected 2026 free cash flow burn is projected to further improve to $(185) million to $(195) million.
• Completed a follow-on public offering and issued convertible senior notes in November 2025, raising net proceeds of $327.3 million and $402.5 million principal amount, respectively.
• Acquired MetaSight Diagnostics in December 2025 for $59.0 million upfront cash, with potential for up to $90.0 million in contingent consideration.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, reflecting robust growth across key segments, improved financial efficiency, and a confident outlook for 2026, despite continued net losses, indicating strong operational momentum and strategic execution.

Positives

• Achieved strong total revenue growth of 39% in Q4 2025 and 33% for the full year 2025, demonstrating robust market demand.
• Oncology test volume increased significantly by 38% in Q4 2025 and 34% for the full year 2025.
• Screening revenue from Shield tests showed exceptional growth, with 38,000 tests in Q4 2025 compared to 6,400 in Q4 2024, and 87,000 tests for the full year 2025.
• Non-GAAP gross margin improved to 66% for both the fourth quarter and full year 2025, indicating enhanced operational efficiency.
• Free cash flow burn improved to $(233) million in 2025 from $(275) million in 2024, with further improvement projected for 2026.
• Received the first Guardant360 CDx companion diagnostic approval in colorectal cancer, expanding market reach.
• Established a strategic collaboration with Merck to develop companion diagnostics and commercialize new cancer therapies.
• Shield CRC received coverage for active-duty service members and their families through TRICARE, expanding access and reimbursement.
• Management expressed confidence in continued strong growth for 2026, fueled by expanding commercial infrastructure and a pipeline of growth drivers.

Negatives

• GAAP net loss increased to $(128.5) million in Q4 2025 from $(111.0) million in Q4 2024.
• GAAP net loss per share increased to $(1.00) in Q4 2025 from $(0.90) in Q4 2024.
• Operating expenses increased significantly year-over-year, primarily due to commercial team expansion and marketing activities to support product launches and growth.
• Licensing and other revenue decreased in both the fourth quarter and full year 2025 compared to the prior year periods.

Risks

• The filing refers to risks and uncertainties discussed under the captions 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operation' in its Annual Report on Form 10-K for the year ended December 31, 2025, and other SEC reports. Specific risks are not detailed within this 8-K or its exhibit.

Future Outlook

Guardant Health expects full year 2026 revenue to be in the range of $1.25 billion to $1.28 billion, representing growth of 27% to 30% compared to full year 2025. Oncology revenue is projected to grow 25% to 27% with approximately 30% increase in volume. Screening revenue is anticipated to be between $162 million and $174 million, with 210,000 to 225,000 Shield tests. Non-GAAP gross margin is expected to be 64% to 65%, and total non-GAAP operating expenses are forecast to increase by 14% to 16%. Free cash flow burn is expected to improve further to a range of $185 million to $195 million in 2026.

Management Comments

• Helmy Eltoukhy, co-founder and co-CEO: "We delivered an outstanding end to a great year, with fourth quarter revenue growth of 39% year-over-year. Our progress in 2025 is a testament to our breakthrough innovation and best-in-class execution across our portfolio. We are uniquely positioned with scaled offerings spanning both therapy selection and monitoring, and the recent launch of Reveal for therapy response monitoring further strengthens our competitive moat. We look forward to another strong year ahead, supported by a diverse set of growth catalysts across our business."
• AmirAli Talasaz, co-founder and co-CEO: "Shield has become one of the most successful diagnostic launches, with meaningful volume and revenue generation in 2025 that exceeded our expectations. We are proud of the level of impact we have had to date, our commercial performance, and the strong operational foundations we’ve built to support the growing demand for Shield. We are excited to deliver another year of significant growth in 2026, fueled by our expanding commercial infrastructure and a pipeline of growth drivers in front of us."

Industry Context

StockSavvy.ai notes that Guardant Health's robust performance in precision oncology and the rapid adoption of its Shield screening test align with the broader industry trend towards non-invasive diagnostics and personalized cancer care. The strategic collaboration with Merck underscores the increasing importance of companion diagnostics in drug development, while the TRICARE coverage for Shield highlights growing payer acceptance for novel screening technologies, positioning Guardant Health as a leader in a rapidly evolving market.

Comparison to Industry Standards

• Guardant Health's 39% Q4 and 33% FY25 revenue growth significantly outpaces many established diagnostic companies, indicating strong market penetration and demand for its liquid biopsy solutions.
• The rapid scaling of Shield screening tests, from 6,400 in Q4 2024 to 38,000 in Q4 2025, demonstrates a faster adoption curve compared to initial launches of similar novel diagnostic tests in the oncology space.
• The improvement in free cash flow burn, from $(275) million in FY24 to $(233) million in FY25, suggests a more efficient path to profitability compared to some early-stage biotech firms that often see increasing cash burn during growth phases.
• The non-GAAP gross margin of 66% is competitive within the high-complexity diagnostic testing sector, reflecting efficient test processing and pricing power.

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue growth, improved cash flow trajectory, and a confident 2026 outlook, which could lead to increased investor confidence and potential share price appreciation. The capital raise provides financial flexibility but also involves some dilution.
• Customers (Patients/Physicians): Positive impact through expanded access to advanced oncology and screening tests (Guardant360 CDx, Guardant Reveal, Shield), new companion diagnostics, and broader insurance coverage (TRICARE), improving patient care options.
• Employees: Potential positive impact from continued commercial team expansion and overall company growth, suggesting job stability and opportunities for career development.
• Partners (Merck): Strengthened collaboration for developing and commercializing new cancer therapies, indicating a robust and mutually beneficial relationship.
• Creditors: Improved financial health, reduced cash burn, and successful capital raises enhance the company's ability to meet its financial obligations, reducing credit risk.

Next Steps

• Continue commercial team expansion and marketing activities to support the Shield product launch and existing product growth.
• Integrate MetaSight Diagnostics technology to enhance testing performance across the portfolio.
• Pursue Medicare reimbursement for Guardant Reveal chemotherapy monitoring data package from MolDx.
• Further develop companion diagnostics and commercialize new cancer therapies through the strategic collaboration with Merck.
• Host a conference call on February 19, 2026, at 1:30 pm Pacific Time / 4:30 pm Eastern Time to discuss the financial results.

Key Dates

Recommendation

The company demonstrates exceptional revenue growth across its core oncology and rapidly expanding screening segments, significantly improving its free cash flow burn and providing a robust 2026 outlook. Strategic partnerships, product approvals, and expanded insurance coverage further solidify its market position and future growth catalysts, making it an attractive investment despite current net losses, as it progresses towards profitability in a high-growth market.

Keywords

precision oncology, liquid biopsy, cancer screening, Guardant360 CDx, Guardant Reveal, Shield, biopharma, diagnostics, cancer therapy, genomic testing, SEC filing, financial results